chapter 1 Drug Discovery and Development / part DEVELOPMENT OF CONGESTIVE HEART FAILURE THERAPY -- chapter 2 Background Therapy in Congestive Heart Failure Studies / chapter 3 Congestive Heart Failure Trial Design / chapter 4 Angiotensin Converting Enzyme Inhibitors for Mortality Reduction in Congestive Heart Failure: Should Approval Be Granted for a Class Effect? -- chapter 5 Sudden Death in Congestive Heart Failure Trials -- chapter 6 Panel Discussion -- part DEVELOPMENT OF ANTIHYPERTENSIVE THERAPY -- chapter 7 Antihypertensive Clinical Trials / chapter 8 Calcium Channel Blockers: Safety Issues / chapter 9 Panel Discussion / part DEVELOPMENT OF ANTIARRHYTHMIC DRUG THERAPY -- chapter 10 Antiarrhythmics: Indications, Claims, and Trial Design / chapter 11 Supraventricular Tachycardia Drugs and Trial Design Issues -- chapter 12 Antiarrhythmic Trials: Update -- chapter 13 Inter-Ethnic Differences in the Susceptibility to Drug- Induced QT Interval Profilongation and Torsade de Pointes / chapter 14 Panel Discussion / part DEVELOPMENT OF ANTILIPID AND ANTI-ISCHEMIC THERAPY -- chapter 15 Antilipid Trial Endpoints / chapter 16 Natural History Endpoints and Angina Trials / chapter 17 Development of Antiplatelet Drugs / chapter 18 Panel Discussion / part CONCLUSION -- chapter 19 Future Directions of Cardiovascular Drug Development / chapter Index -- chapter About the Editors.